Open AccessVaccines against human papilloma virus and cervical cancer: An overview
Author(s) -
Sanjeev Sharma
Publication year - 2008
Publication title -
indian journal of community medicine/indian journal of community medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.375
H-Index - 32
eISSN - 1998-3581
pISSN - 0970-0218
DOI - 10.4103/0970-0218.42045
Subject(s) - cervical cancer , gardasil , medicine , genital warts , human papilloma virus , hpv vaccines , cancer , disease , gynecology , hpv infection
The paradigm of preventing human papilloma virus (HPV) infection through currently approved vaccines, namely, Gardasil, manufactured by Merck and Co., Inc. (Whitehouse Station, NJ) and Cervarix, manufactured by GlaxoSmithKline (GSK, Philadelphia) holds tremendous promise for the developing countries in decreasing the burden of HPV infection and its sequelae, such as cervical cancer, genital warts and anogenital cancers. Effective screening programs that have reduced the burden of this killer disease in the developed countries are still lacking in India, despite the high incidence of cervical cancer and the implementation of the National Cancer Control Programme since 1975. The recent breakthrough in the global war against cervical cancer will provide new insight for meeting the future challenge of the prevention of cervical cancer in India.